Fast Screening Tests for Early Detection of Gastric Cancer

2020 ◽  
Vol MA2020-02 (66) ◽  
pp. 3330-3330
Author(s):  
Raluca Van Staden ◽  
Ruxandra Maria Ilie-Mihai ◽  
Damaris Cristina Gheorghe
2021 ◽  
Vol MA2021-02 (56) ◽  
pp. 1655-1655
Author(s):  
Raluca Van Staden ◽  
Ruxandra Maria Ilie-Mihai ◽  
Damaris Cristina Ghrorghe ◽  
Iuliana Mihaela Bogea

2020 ◽  
Vol 72 (4) ◽  
pp. 22-34
Author(s):  
Ruxandra-Maria Ilie-Mihai ◽  
Damaris-Cristina Gheorghe ◽  
Raluca-Ioana Stefan-Van Staden ◽  
Alexandrina Lungu-Moscalu ◽  
Maria Coros ◽  
...  

Early detection of cancer is essential for saving the life of patients. Needle stochastic sensors were proposed as new tools for the fast screening of biological samples. The design of the stochastic sensors was based on the immobilization of protoporphyrin IX in pastes of S-doped graphene. The selected biomarkers were CEA and CA19-9. High sensitivities, and wide linear concentration ranges as well as low limits of quantification were achieved. The proposed sensors were validated; student t-test shown that the proposed needle stochastic sensors can be reliably used for the pattern recognition and quantification of CEA and CA19-9 in whole blood, gastric tumor tissue, saliva, and urine.


2001 ◽  
Vol 120 (5) ◽  
pp. A606-A606
Author(s):  
Y MORII ◽  
T YOSHIDA ◽  
T MATSUMATA ◽  
T ARITA ◽  
K SHIMODA ◽  
...  

2015 ◽  
Vol 8 (3) ◽  
pp. 59 ◽  
Author(s):  
Qader Motarjemizadeh ◽  
Naser Samadi Aidenloo ◽  
Mohammad Abbaszadeh

<p>Hydroxychloroquine (HCQ) is an antimalarial drug used extensively in treatment of autoimmune diseases such as rheumatoid arthritis. Retinal toxicity is the most important side effects of this drug. Even after the drug is discontinued, retinal degeneration from HCQ can continue to progress. Consequently, multiple ophthalmic screening tests have been developed to detect early retinopathy. The aim of the current study was to evaluate the value of central 2-10 perimetry method in early detection of retinal toxicity. This prospective cross-sectional investigation was carried out on 60 rheumatoid arthritis patients, who had been receiving HCQ for at least 6 months and still were on their medication (HCQ intake) at the time of enrollment. An ophthalmologist examined participants using direct and indirect ophthalmoscopy. Visual field testing with automated perimetry technique (central 2-10 perimetry with red target) was performed on all included subjects twice in 6 months interval: The first one at the time of enrollment and the second one 6 months later. Males and females did not show any significant difference in terms of age, duration of therapy, daily and cumulative HCQ dose, anterior or posterior segment abnormalities, hypertension, body mass index, and best corrected visual acuity. Anterior segment was abnormal in 9 individuals including 3 subjects with macular pigmentary changes, 4 individuals with cataract and 2 cases with dry eyes. Moreover, 12 subjects had retinal pigmented epithelium (RPE) in their posterior segments. After 6 months, depressive changes appeared in 12 subjects. Additionally, HCQ therapy worsened significantly the perimetric results of 5 (55.6%) patients with abnormal anterior segment. A same trend was observed in perimetric results of 6 (50.0%) subjects with abnormal posterior segments (P=0.009). The daily dose of HCQ (P=0.035) as well as the cumulative dose of hydroxychloroquine (P=0.021) displayed statistically significant associations with perimetric results. Central 2-10 perimetry is a useful method for early detection of HCQ retinal toxicity, but more comprehensive studies, with larger sample size, longer-term follow-up and more precise techniques are mandatory to confirm HCQ retinal toxicity.</p>


2018 ◽  
Vol 18 (1) ◽  
pp. 82 ◽  
Author(s):  
Jie-Hyun Kim ◽  
Sung Soo Kim ◽  
Jeong Hoon Lee ◽  
Da Hyun Jung ◽  
Dae Young Cheung ◽  
...  

2016 ◽  
Vol 150 (4) ◽  
pp. S871
Author(s):  
Hiroyuki Yamamoto ◽  
Yoshihito Yoshida ◽  
Ryo Morita ◽  
Ritsuko Oikawa ◽  
Tadateru Maehata ◽  
...  

2007 ◽  
Vol 2 ◽  
pp. 117727190700200 ◽  
Author(s):  
Michael A. Tainsky ◽  
Madhumita Chatterjee ◽  
Nancy K. Levin ◽  
Sorin Draghici ◽  
Judith Abrams

It has become very clear that a single molecular event is inadequate to accurately predict the biology (or pathophysiology) of cancer. Furthermore, using any single molecular event as a biomarker for the early detection of malignancy may not comprehensively identify the majority of individuals with that disease. Therefore, the fact that technologies have arisen that can simultaneously detect several, possibly hundreds, of biomarkers has propelled the field towards the development of multianalyte-based in vitro diagnostic early detection tests for cancer using body fluids such as serum, plasma, sputum, saliva, or urine. These multianalyte tests may be based on the detection of serum autoantibodies to tumor antigens, the presence of cancer-related proteins in serum, or the presence of tumor-specific genomic changes that appear in plasma as free DNA. The implementation of non-invasive diagnostic approaches to detect early stage cancer may provide the physician with evidence of cancer, but the question arises as to how the information will affect the pathway of clinical intervention. The confirmation of a positive result from an in vitro diagnostic cancer test may involve relatively invasive procedures to establish a true cancer diagnosis. If in vitro diagnostic tests are proven to be both specific, i.e. rarely produce false positive results due to unrelated conditions, and sufficiently sensitive, i.e. rarely produce false negative results, then such screening tests offer the potential for early detection and personalized therapeutics using multiple disease-related targets with convenient and non-invasive means. Here we discuss the technical and regulatory barriers inherent in development of clinical multianalyte biomarker assays.


Sign in / Sign up

Export Citation Format

Share Document